A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

A PHASE 2, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-07868489 ADMINISTERED TO ADULT PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250407

Enrollment

Registered

2025-10-02

Start date

2025-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Interventions

*Drug: PF-07868489 Participants will receive subcutaneous doses of PF-07868489 every 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: *Is aged 18 years or older at the time of screening for the previous study and has completed the required treatment duration with PF-07868469, as well as all other assessments at the end of that study. *Is willing and able to comply with all scheduled visits, the treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

Exclusion criteria

Exclusion criteria: *Has experienced worsening of PAH or has been hospitalized due to worsening PAH during the qualifying study. *Is scheduled for surgery to replace any tissue or part of the body (transplant), or has planned surgery related to PAH. *Has an ongoing major health issue during the qualifying study that, in the opinion of the study doctor, could disqualify the participant from this study. *Is currently suffering from, or has previously suffered from, hepato-pulmonary syndrome (a liver-related lung condition). *Is currently prescribed or taking medications known as GLP-1 agonists.

Design outcomes

Primary

Measure	Time frame
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [Time Frame: Baseline up to week 111] Number of Participants With Change From Baseline in Laboratory Tests Results [Time Frame: Baseline up to week 111] *Number of Participants With Vital Sign Abnormalities [Time Frame: Baseline up to week 111]	—

Secondary

Measure	Time frame
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration [Time Frame: Baseline up to week 104] Minimum Observed Plasma Trough Concentration (Cmin), as data permits [Time Frame: Baseline up to week 111] *Incidence of Anti-Drug Antibody (ADA) [Time Frame: Baseline up to week 111]	—

Countries

Australia, Belgium, Canada, China, Czechia, France, Germany, Greece, Italy, Japan, South Korea, Spain, United Kingdom, United States

Contacts

Public ContactClinical Trials Information Desk

Pfizer R&D Japan G.K.

clinical-trials@pfizer.com+81-3-5309-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026